Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.

ABSTRACT: The B-cell maturation antigen (BCMA) is currently being evaluated as promising tumor-associated surface antigen for T-cell-based immunotherapy approaches, such as CAR T cells and bispecific antibodies, in multiple myeloma (MM). Cytotoxic T cells bearing BCMA-specific T-cell receptors might further allow targeting HLA-presented antigens derived from the intracellular domain of BCMA. By analyzing a mass spectrometry-acquired immunopeptidome dataset of primary MM samples and MM cell lines for BCMA-derived HLA ligands, we identified the naturally presented HLA-B*18-restricted ligand P(BCMA)_B*18. Additionally, P(BCMA)_B*18 was identified on primary CLL samples, thereby expanding the range for possible applications. P(BCMA)_B*18 induced multifunctional BCMA-specifi

SUBMITTER: Bilich T 

PROVIDER: S-EPMC7048774 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature